Joubert Syndrome
Introduction to Joubert Syndrome
Joubert syndrome is a type of genetic disease that can cause brain abnormalities and make the body out of control. In the past few years of studies, many reports have demonstrated that Joubert syndrome is associated with the dysfunction of the vermis of the cerebellum and the brain stem. Pilot studies have shown that the cerebellum, a key portion of the brain, plays a significant role in regulating the balance and coordination of humans. The brain stem is essential for the connection between the brain and the spinal cord. As a result, patients suffer from Joubert syndrome presented with periodic breathing, rapid eye movements, hypotonia, cognitive disorder as well as seizures.
Fig.1 Clinical subtypes of Joubert syndrome and related disorders. (Ben-Salem, 2014)
Key Factors in Joubert Syndrome
Joubert syndrome is an autosomal recessive disease that can be characterized by the deformity of the brainstem and hypoplasia of the cerebellar vermis. Previous studies have indicated that a key factor for the occurrence and development of Joubert syndrome is mutations in 30 or more genes in humans. It often occurs by familial inheritance or environmental influence. In general, mutations can lead to cilia form in error, which further affects the transmission of signals among cells. Up to now, mutations caused by Joubert syndrome are mainly be found in autosomal and only one known mutation in chromosome X. For example, a wide variety of genes, including but not limited to, AHI1, MKS1, TCTN2, CPLANE1, TMEM67, CEP290, and NPHP1, have been identified and have been broadly used for revealing the mechanism of Joubert syndrome.
Treatment for Joubert Syndrome
Nowadays, Joubert syndrome has been divided into several subtypes, such as pure Joubert syndrome, Joubert syndrome with ocular defect, renal defect, oculorenal defects, hepatic defect, or oro-facio-digital defects based on specific tissues. Therefore, Joubert syndrome can affect many parts of the human body and lead to serious clinical symptoms. For the treatment, the common method for the treatment of patients with Joubert syndrome needs certain medications, assistive devices, and surgery, like caffeine, oxygen, tracheostomy. Moreover, some new interventions are also becoming standard treatments for the disease. Among them, speech therapy and physical therapy have been considered as popular strategies for managing special patients with Joubert syndrome.
Besides, Joubert syndrome-associated genetic screening has become a research hotspot in recent years and the data can provide meaningful support for screening individuals who carry high-risk genetic variations of Joubert syndrome. Meanwhile, a range of advanced technologies, including next-generation sequencing, SNP genotyping, and exome sequencing, have been used for analyzing genes in different populations. For instance, to identify novel genes, whole-exome sequencing screening systems have been established on 400 French Canadian individuals with Joubert syndrome. The results have suggested that four variations in the C5ORF42 gene should be founder mutations and may be a cause of Joubert syndrome in the French Canadian population.
Recently, many neuroscience research and drug development efforts have been made to the treatment of Joubert syndrome. A wide variety of novel products, like antibodies, proteins, as well as peptides, have been generated and evaluated in many Joubert syndrome-based animal models. These models can provide meaningful data for elucidating the pathogenic mechanism of Joubert syndrome in the future.
Currently, Creative Biolabs provides a global service chain for worldwide customers in the field of Joubert syndrome research. We guarantee the finest results for our customers all over the world. If you are interested in our services, please feel free to contact us for closer communication to learn how we can be involved in your project. Separate services or integrated end-to-end solutions are all welcomed.
Reference
- Ben-Salem, S.; et al. Mutation spectrum of Joubert syndrome and related disorders among Arabs. Human genome variation. 2014, 1(1): 1-10.
- NeuroMab™ Anti-ApoC3 BBB Shuttle Antibody(NRZP-1022-ZP3505) (Cat#: NRZP-1022-ZP3505)
- NeuroMab™ Anti-TREM2 BBB Shuttle Antibody(NRZP-1022-ZP4114) (Cat#: NRZP-1022-ZP4114)
- NeuroMab™ Anti-ApoC3 BBB Shuttle Antibody(NRZP-1022-ZP3503) (Cat#: NRZP-1022-ZP3503)
- NeuroMab™ Anti-SEZ6 Antibody(NRP-0422-P515) (Cat#: NRP-0422-P515)
- NeuroMab™ Anti-Alpha Synuclein BBB Shuttle Antibody(NRZP-1022-ZP4050) (Cat#: NRZP-1022-ZP4050)
- NeuroMab™ Anti-TNFα BBB Shuttle Antibody(NRZP-1022-ZP4105) (Cat#: NRZP-1022-ZP4105)
- NeuroMab™ Anti-FGFR1 Antibody(NRP-0422-P1244) (Cat#: NRP-0422-P1244)
- NeuroMab™ Anti-Alpha Synuclein Antibody(NRP-0422-P614) (Cat#: NRP-0422-P614)
- NeuroMab™ Anti-GD2 Antibody(NRZP-1222-ZP767) (Cat#: NRZP-1222-ZP767)
- NeuroMab™ Anti-Tau Antibody(NRP-0422-P1686) (Cat#: NRP-0422-P1686)
- Rat Glioma Cell Line C6 (Cat#: NCL2110P346)
- iNeu™ Human Motor Neurons (Cat#: NCL-2103-P71)
- Human Glioblastoma Cell Line SF126 (Cat#: NCL-2108P35)
- iNeu™ Human Schwann Cell (Cat#: NCL-2103-P63)
- Immortalized Human Cerebral Microvascular Endothelial Cells (Cat#: NCL-2108-P020)
- Human Microglia Cell Line HMC3, Immortalized (Cat#: NCL-2108P38)
- Green Fluorescent Alpha-synuclein SH-SY5Y Cell Line (Cat#: NCL2110P209)
- Mouse Microglia from C57BL/6 (Cat#: NCL-21P6-082)
- iNeu™ Human Midbrain Dopaminergic Neurons (Cat#: NCL-21P6-003)
- Rat Retinal Muller Cell Line, Immortalized (Cat#: NCL-21P6-192)
- Human GFAP ELISA Kit [Colorimetric] (Cat#: NPP2011ZP383)
- Alpha Synuclein Aggregation Kit (Cat#: NRZP-1122-ZP15)
- Beta Amyloid (1-42), Aggregation Kit (Cat#: NRZP-0323-ZP200)
- Human Tau Aggregation Kit (Cat#: NRP-0322-P2173)
- Beta Amyloid (1-40), Aggregation Kit (Cat#: NRZP-0323-ZP199)
- Alpha-Synuclein Aggregation Assay Kit (Cat#: NRZP-1122-ZP37)
- Human Poly ADP ribose polymerase,PARP Assay Kit (Cat#: NRZP-1122-ZP62)
- Amyloid beta 1-42 Kit (Cat#: NRP-0322-P2170)
- rAAV-CAG-DIO-G-Flamp1 (Cat#: NRZP-0722-ZP719)
- Dextran, Cy5 Labeled, 2000 kDa (Cat#: NRZP-0722-ZP22)
- pAAV-syn-FLEX-jGCaMP8s-WPRE (Cat#: NTA-2106-P066)
- pAAV-syn-jGCaMP8s-WPRE (Cat#: NTA-2106-P063)
- pAAV-syn-FLEX-jGCaMP8m-WPRE (Cat#: NTA-2106-P065)
- Dextran-FITC (Cat#: NTA-2011-ZP110)
- Dextran, NHS Activated, 40 kDa (Cat#: NRZP-0722-ZP124)
- PRV-CAG-EGFP (Cat#: NTA-2011-ZP14)
- VSV-eGFP (Cat#: NTA-2011-ZP20)
- pAAV-syn-FLEX-jGCaMP8f-WPRE (Cat#: NTA-2106-P064)
- Human huntingtin (HTT) (NM_002111) ORF clone, Myc-DDK Tagged (Cat#: NEP-0521-R0497)
- Mouse SOD1 shRNA Silencing Adenovirus (Cat#: NV-2106-P14)
- Mouse Parkinson disease (autosomal recessive, early onset) 7 (Park7) (NM_020569) clone, Untagged (Cat#: NEP-0621-R0133)
- App Rat amyloid beta (A4) precursor protein (App)(NM_019288) ORF clone, Untagged (Cat#: NEP-0421-R0053)
- Human superoxide dismutase 1, soluble (SOD1) (NM_000454) ORF clone, TurboGFP Tagged (Cat#: NEP-0521-R0748)
- Lenti of Human TAR DNA binding protein (TARDBP) (NM_007375) ORF clone, mGFP Tagged (Cat#: NEP-0521-R0832)
- Human huntingtin-associated protein 1 (HAP1) transcript variant 2 (NM_177977) ORF clone, Myc-DDK Tagged (Cat#: NEP-0521-R0676)
- Tau Antisense Oligonucleotide (IONIS-MAPTRx) (Cat#: NV-2106-P29)
- Human apolipoprotein E (APOE) (NM_000041) ORF clone, Untagged (Cat#: NEP-0421-R0232)
- Rat Parkinson disease (autosomal recessive, juvenile) 2, parkin (Park2) (NM_020093) ORF clone/lentiviral particle, Myc-DDK Tagged (Cat#: NEP-0621-R0041)
- NeuroBiologics™ Human Cerebrospinal Fluid (Cat#: NRZP-0822-ZP491)
- NeuroBiologics™ Mouse Cerebrospinal Fluid (Cat#: NRZP-0822-ZP497)
- NeuroBiologics™ Pig Cerebrospinal Fluid (Cat#: NRZP-0822-ZP498)
- NeuroBiologics™ Monkey Cerebrospinal Fluid (Cat#: NRZP-0822-ZP495)
- NeuroBiologics™ Rat Cerebrospinal Fluid (Cat#: NRZP-0822-ZP496)
- NeuroPro™ Anti-GDNF BBB Shuttle Protein (Cat#: NRZP-0423-ZP509)
- NeuroPro™ Anti-IDUA BBB Shuttle Protein (Cat#: NRZP-0423-ZP498)
- NeuroPro™ Anti-SGSH BBB Shuttle Protein (Cat#: NRZP-0423-ZP505)
- NeuroPro™ Anti-idursulfase BBB Shuttle Protein (Cat#: NRZP-0423-ZP497)
- NeuroPro™ Anti-PON1 BBB Shuttle Protein (Cat#: NRZP-0423-ZP507)
- NeuroPro™ Anti-NAGLU BBB Shuttle Protein (Cat#: NRZP-0423-ZP506)
- NeuroPro™ Anti-GDNF BBB Shuttle Protein (Cat#: NRZP-0423-ZP500)
- NeuroPro™ Anti-TNFR BBB Shuttle Protein (Cat#: NRZP-0423-ZP510)
- NeuroPro™ Anti-Erythropoietin BBB Shuttle Protein (Cat#: NRZP-0423-ZP499)
- NeuroPro™ Anti-ASA BBB Shuttle Protein (Cat#: NRZP-0423-ZP504)